{
    "pmcid": "8514607",
    "qa_pairs": {
        "How can synthetic nanobodies, or sybodies, be engineered for therapeutic applications?": [
            "By improving binding affinity and stability",
            "By increasing their molecular weight",
            "By reducing their solubility",
            "By decreasing their specificity for target antigens"
        ],
        "What is a potential benefit of formulating nanobodies for inhalation in treating SARS-CoV-2 infections?": [
            "Direct delivery to the respiratory tract where SARS-CoV-2 primarily infects",
            "Increased systemic circulation time",
            "Enhanced ability to cross the blood-brain barrier",
            "Reduced risk of developing resistance"
        ],
        "What is one advantage of nanobodies over traditional antibodies in therapeutic applications?": [
            "Their small size allows for better tissue penetration and potential for pulmonary administration",
            "They are more effective at crossing the blood-brain barrier",
            "They have a longer half-life in the bloodstream",
            "They are less expensive to produce"
        ],
        "What is the primary target for neutralizing antibodies, including nanobodies, in SARS-CoV-2?": [
            "The receptor-binding domain (RBD) of the spike protein",
            "The nucleocapsid protein",
            "The membrane protein",
            "The envelope protein"
        ],
        "Which mutations in the SARS-CoV-2 spike protein are associated with increased resistance to neutralizing antibodies?": [
            "E484K and N501Y",
            "D614G and L452R",
            "P681R and T478K",
            "K417N and Y453F"
        ]
    }
}